Basel, Switzerland (ots/PRNewswire) - - Parkinson's Patients Who Require the Start of Levodopa Therapy May Be Eligible to Participate in This Study Novartis and Orion Pharma announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended that Avastin (bevacizumab) in combination with intravenous ...
Basel, Switzerland (ots/PRNewswire) - Key figures First nine months Nine months 2004 Nine months 2003 % Change USD m % of sales USD m % of sales USD lc[1] Sales 20 669 18 134 14 9 Pharmaceutical 11 641 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R. Debregeas to its board of directors. As Chairman, CEO and President of Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas brings extensive international experience in the pharmaceutical ...
Buenos Aires, Argentina (ots/PRNewswire) - -- Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience -- An international study conducted in 21 countries showed that 82 percent of men with ED who were treated with 20 mg ...
Copenhagen, Denmark (ots/PRNewswire) - Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice ...
Basel, Switzerland (ots/PRNewswire) - Today, HIV drug Fuzeon (enfuvirtide or T-20) was awarded the 2004 International Prix Galien for the most innovative new medicine. Fuzeon was selected out of 12 major new drugs in all therapeutic areas which each won national awards. Since 1970 Roche has won a total of 24 ...
Wolters Kluwer Health, Pharma Solutions
Chester, England (ots/PRNewswire) - - Accepts Prestigious 2004 'Investors in People' Award Wolters Kluwer Health, Pharma Solutions business unit today announced that Adis International was named a 2004 "Investor in People" by the Investors in People UK Recognition Panel. The London-based organization assesses corporate business practices against a national ...
Madrid (ots/PRNewswire) - The United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to Yondelis in the indication of Soft Tissue Sarcoma (STS). The sponsor of this application in the US is our partner Johnson & Johnson Pharmaceutical Research & Development. The European Commission (E.C.) already granted Orphan Drug status for this ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Aplidin(R), its second marine-derived compound in Phase II clinical development, has been granted orphan drug status by the United States (US) Food and Drug Administration (FDA), for the treatment of Multiple Myeloma (MM). This is the second orphan drug designation granted to Aplidin by the FDA. The ...
Geneva, Switzerland (ots/PRNewswire) - PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR[1] International Conference on Molecular Targets and Cancer Therapeutics, held in Geneva, Switzerland, from 28 September to 1 October 2004. ...
Montreal (ots/PRNewswire) - ProMetic Life Sciences (PLI:TSX) announced today the administrative reorganisation of its communications and business development structure. By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the United States, Europe, Asia and the Middle East. ProMetic can better achieve this goal ...
Zurich (ots) - The Swiss-based company Prionics AG has won the most highly acclaimed European Biotech Award, the European Biotechnica Award for Excellence in Biotech Business. The award was handed over yesterday at the Biotechnica Business Forum in Berlin by the German Federal Minister of Economic Affairs, Wolfgang Clement. The international jury awarded the Biotech prize for Prionics' excellent track record both ...
Vienna, Austria (ots/PRNewswire) - - Prograf(R)-sirolimus Combination is Effective in Kidney Transplantation - Clinical Benefits With Prograf(R) for Heart Transplant Patients Six-month data from a new European study, presented today by Dr Stefan Vitko (IKEM, Prague, Czech Republic) at the XX International Congress of the Transplantation Society, ...
Dr Patrick Marcellin, Beaujon Hospital
Paris (ots/PRNewswire) - - World Experts Meet in Paris for the First International Conference on the Management of Patients With Viral Hepatitis The world's leading hepatitis experts, along with more than 850 physicians, will be meeting in Paris on September 10 and 11 for the first International Conference on the Management of Patients with Viral Hepatitis. The conference will review the most ...
Houston (ots/PRNewswire) - - Study Shows Liver Toxicities Experienced by Patients on Bosentan Were Not Experienced on Thelin Encysive Pharmaceuticals (Nasdaq: ENCY) today announced the presentation of new clinical data on Thelin(TM) (sitaxsentan) in pulmonary arterial hypertension (PAH), at the European ...
Munich, Germany (ots/PRNewswire) - - Researchers conclude LAF237 positively influences both insulin production and utilisation in type 2 diabetes The investigational drug LAF237, the first in a new class of oral anti- diabetes agents, significantly improved glycemic control in patients with type 2 ...
Vienna, Austria (ots/PRNewswire) - Transplant specialists from around the world met yesterday to discuss controversial, radical and novel approaches to minimise the impact of the current organ shortage problem in a bid to help desperate patients in need of a kidney transplant. The full-day symposium, which ...
London and Brussels (ots/PRNewswire) - - RISC Study, Largest of its Kind, Reaches Recruitment Milestone The European Group for the study of Insulin Resistance (EGIR) announced today that the clinical trial recruitment milestone of 1,200 subjects has been reached in the Relationship between Insulin Sensitivity and Cardiovascular disease risk (RISC) study - ...
Montreal (ots/PRNewswire) - - Potential use Includes Anaemia Induced by Chemotherapy and Renal Diseases - Market of Above US$10 Billion ProMetic Life Sciences Inc. (TSX: PLI) is pleased to announce that its scientists have confirmed evidence of PBI-1402's positive effect on the formation of red blood cells in bone marrow. This proliferation is additive ...
Copenhagen, Denmark (ots/PRNewswire) - Genmab A/S (CSE: GEN) announced today that cutaneous T-cell lymphoma (CTCL) patients in the HuMax-CD4 Phase II studies achieved long lasting responses, with an average response duration of more than 6.6 months. This duration of response data is based on an analysis of responding mycosis fungoides (MF) patients at all dose ...
Houston (ots/PRNewswire) - - Abstract Presented on Extension Data From STRIDE-1 Trial in Pulmonary Arterial Hypertension Encysive Pharmaceuticals (Nasdaq: ENCY) today announced the presentation of data from a clinical study of Thelin(TM) (sitaxsentan) in pulmonary arterial hypertension (PAH), at the European Society of Cardiology Annual Congress in Munich. ...
Munich, Germany (ots/PRNewswire) - - Data from this and other Diovan(R)(valsartan) studies, including VALIANT and Val-HeFT presented at the European Society Congress 2004 An analysis of more than 39,000 potential participants in the global NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance ...
Basel, Switzerland (ots/PRNewswire) - - Roche files marketing application for Tarceva with European health authorities Roche today submitted a Marketing Authorisation Application to the European health authorities for its new cancer drug Tarceva (erlotinib) for the treatment of advanced non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer, which in itself is the most frequent cancer ...
Basel, Switzerland (ots/PRNewswire) - - 4.5 Million Americans Suffer from Constipation Most of the Time Novartis Pharma AG announced that the U.S. Food and Drug Administration (FDA) today approved a supplemental indication for its pro-motility agent Zelnorm(R) (tegaserod maleate) for the treatment of chronic idiopathic constipation in male and female ...
Tampere, Finland (ots/PRNewswire) - Inion, one of the leading companies in the field of developing biodegradable medical implants, announces FDA 510(k) clearance of its Trinion(TM) Meniscus Screw for use in knee cartilage repair. This clearance allows Inion's Trinion(TM) screws to be marketed and sold in the US, complementing the previously offered HexalonTM biodegradable cruciate ligament repair screw, in the world's ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Strong net new business growth, up 31% for first half of 2004 - Fourth consecutive half-year increase in total net new business wins Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2004. Net revenue for second quarter 2004 was US$425.8 million versus US$408.4 million for the same period in 2003. Net ...
Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - Please add the following ticker symbols to the first paragraph of the release. (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) IsoTis OrthoBiologics (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six ...
/ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics, EDB1011437 Please place the following release: "IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance" ON HOLD. ots Originaltext: IsoTis OrthoBiologics Im Internet recherchierbar: http://www.newsaktuell.ch Contact: Hans Herklots, +41-21-620-6011, Fax: +41-21-620-6060, hans.herklots@isotis.com, or Louis G. Plourde, ...